Researchers at Gladstone Institutes reported in the journal Nature Medicine that they were able to neutralize the gene for apolipoprotein E4, associated with a high risk for Alzheimer's disease, and restored normal function to the brain cells. The researchers will now work with the pharmaceutical industry on clinical trials of the structure-correcting compound.
Structure corrector neutralizes protein linked to Alzheimer's disease
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.